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Abstract
Introduction  and  objectives:  Hypertrophic  cardiomyopathy  (HCM)  is  a  genetically  and  pheno-
typically  heterogeneous  disease;  there  is  still  a  large  proportion  of  patients  with  no  identified
disease-causing  mutation.  Although  the  majority  of  mutations  are  found  in  the  MYH7  and
MYBPC3 genes,  mutations  in  Z-disk-associated  proteins  have  also  been  linked  to  HCM.
Methods:  We  assessed  a  small  family  with  HCM  based  on  family  history,  physical  examination,
12-lead  ECG,  echocardiogram  and  magnetic  resonance  imaging.  After  exclusion  of  mutations
in eleven  HCM  disease  genes,  we  performed  direct  sequencing  of  the  TCAP  gene  encoding  the
Z-disk protein  titin-cap  (also  known  as  telethonin).
Results:  We  present  a  novel  TCAP  mutation  in  a  small  family  affected  by  HCM.  The  identified
p.C57W mutation  showed  a  very  low  population  frequency,  as  well  as  high  conservation  across
species.  All  of  the  bioinformatic  prediction  tools  used  considered  this  mutation  to  be  damag-
ing/deleterious.  Family  members  were  screened  for  this  new  mutation  and  a  co-segregation
pattern was  detected.  Both  affected  members  of  this  family  presented  with  late-onset  HCM,
moderate asymmetric  left  ventricular  hypertrophy,  atrial  fibrillation  and  heart  failure  with
preserved ejection  fraction  and  low  risk  of  sudden  cardiac  death.
Conclusions:  We  present  evidence  supporting  the  classification  of  the  TCAP  p.C57W  muta-
tion, encoding  the  Z-disk  protein  titin-cap/telethonin  as  a  new  likely  pathogenic  variant  of
hypertrophic  cardiomyopathy,  with  a  specific  phenotype  in  the  family  under  analysis.sa  de  Cardiologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
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Identificac¸ão  de  uma  nova  mutac¸ão no  gene  TCAP/Teletonina  numa  família
portuguesa  com  miocardiopatia  hipertrófica
Resumo
Introduc¸ão  e  objetivos:  A  miocardiopatia  hipertrófica  (HCM)  é  uma  doenc¸a  genética  e  fenotipi-
camente heterogénea,  existindo  ainda  uma  grande  proporc¸ão  de  doentes  sem  uma  mutac¸ão
patogénica  identificada.  Embora  a  maioria  das  mutac¸ões  seja  encontrada  nos  genes  MYH7  e
MYBPC3,  mutac¸ões  em  proteínas  associadas  ao  disco  Z  também  foram  associadas  à  HCM.
Métodos:  Avaliámos  uma  pequena  família  com  HCM  com  base  na  história  familiar  e  exame
objetivo,  eletrocardiograma  de  12  derivac¸ões,  ecocardiograma  e  ressonância  magnética.  Após
exclusão de  mutac¸ões  em  11  genes  causadores  de  HCM,  realizámos  a  sequenciac¸ão  direta  do
gene TCAP  que  codifica  a  proteína  titin-cap  do  disco-Z  (também  conhecida  como  teletonina).
Resultados:  Relatamos  aqui  uma  nova  mutac¸ão  do  gene  TCAP  numa  pequena  família  com  HCM.
A mutac¸ão  identificada,  p.C57W,  mostrou  uma  frequência  populacional  muito  baixa,  bem  como
alta conservac¸ão  entre  as  espécies.  Todas  as  ferramentas  de  previsão  de  bioinformática  usadas
previram que  essa  mutac¸ão  seria  funcionalmente  prejudicial.  A  presenc¸a  desta  nova  mutac¸ão
foi avaliada  nos  outros  membros  da  família,  tendo-se  detetado  um  padrão  de  cossegregac¸ão.
Ambos os  membros  da  família  afetados  apresentaram  HCM  de  início  tardio,  com  hipertrofia
ventricular  esquerda  assimétrica  moderada,  fibrilhac¸ão  auricular  e  insuficiência  cardíaca  com
fracão de  ejec¸ão  preservada,  com  baixo  risco  de  morte  súbita  cardíaca.
Conclusão:  Apresentamos  evidência  que  suporta  a  classificac¸ão  da  mutac¸ão  TCAP  p.C57W,  que
codifica a  proteína  titin-cap  do  disco-Z  (teletonina),  como  uma  nova  variante  provavelmente
patogénica  da  HCM,  com  um  perfil  fenotípico  específico  na  família  analisada.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´ um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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extracted  from  EDTA  blood  using  the  method  described
by  Lahiri  et  al.15 Primer  pairs  were  designed  to  amplifyntroduction
arcomeric  hypertrophic  cardiomyopathy  (HCM)  is  a  mono-
enic  disorder  that  is  often  familial.1,2 Transmission  of
he  disease  is  autosomal  dominant  and  it  is  caused  classi-
ally  by  mutations  in  genes  that  encode  cardiac  sarcomere
roteins.1,2 However,  in  patients  with  the  HCM  phenotype,
he  classic  sequencing  of  sarcomere  protein  genes  only  iden-
ifies  a  disease-causing  mutation  in  about  50-60%  of  cases.3
ntensive  research  is  increasing  the  available  genetic  infor-
ation  available  on  this  disease.  Recently,  formin  homology
 domain  containing  3  (FHOD3)  was  proposed  as  a  novel
isease  gene  in  HCM.  It  accounts  for  approximately  1%  to
%  of  all  HCM  cases.4 Mutations  in  Z-disk-associated  pro-
eins  have  also  been  linked  to  HCM5,6 and  may  partially
xplain  some  of  the  negative  genetic  tests  for  sarcomeric
CM.  Several  HCM-susceptibility  genes,  which  encode  Z-
isk  proteins,  have  been  discovered,  including  actin  alpha  2
ACTN2),7 myozenin  2  (MYOZ2),8 muscle  LIM  protein  (MLP),9
nd  telethonin  (TCAP).10 Until  the  present  moment,  very
ew  mutations  in  TCAP  encoding  titin-cap  (also  known  as
elethonin)  causing  cardiomyopathies  have  been  identified
OMIM  604488).
We  present  the  case  of  a  family  with  HCM,  in  whom  we
xcluded  mutations  in  the  eleven  classic  sarcomeric  disease-
ausing  genes.  We  further  analyzed  the  TCAP  gene,  whichPlease  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
ed  to  the  identification  of  the  probable  disease-causing
utation  p.C57W,  co-segregating  with  the  family’s  pheno-
ype.
t
sethods
henotyping
he  two  known  affected  members  of  the  family  were  exam-
ned  at  an  HCM  tertiary  referral  center  (Hospital  da  Luz
-  Lisbon,  Portugal).  Both  individuals  were  followed  up
ccording  to  the  guidelines,3,11 with  ECG,  echocardiogram,
4-h  Holter  monitoring,  treadmill  exercise  test,  and  car-
iac  magnetic  resonance  (CMR),  when  available.  These  tests
ere  performed  at  regular  intervals  and  whenever  there
as  a  clinical  indication.  The  HCM  diagnosis  was  based
n  the  established  criteria.3,11--13 The  local  institutional
eview  board  approved  the  study  and  informed  consent
as  obtained.  The  study  protocol  complies  with  the  ethical
uidelines  of  the  1975  Declaration  of  Helsinki.
enetic  analysis
he  TCAP  gene  is  located  on  chromosome  17q12
assembly  Genome  Reference  Consortium  Human  Build
8  patch  release  13  (GRCh38.p13)),  location  NC  000017.11
39665349.  .  .39666554).  Genetic  analysis  of  TCAP  was
erformed  as  previously  described.6,14 Genomic  DNA  was of  a  novel  titin-cap/telethonin  mutation  in  a  Portuguese
20.  https://doi.org/10.1016/j.repc.2019.12.007
he  two  coding  exons  of  TCAP  with  flanking  intronic
equences  based  on  the  published  sequence  GenBank  (at
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Identification  of  a  novel  titin-cap/telethonin  mutation  in  a  f
ncbi/HYPERLINK’’http://nlm.nih.gov/genbank/’’nlm.nih.
gov/genbank/).  While  one  primer  pair  was  used  for  exon
1  (Tel1),  we  used  three  overlapping  primer  pairs  for  exon
2  to  cover  its  large  size  of  393  bp  (Tel2-4).  All  gene-
specific  sequences  (18-20  bp)  were  preceded  by  18  bp  of
M13  sequence  (forward  and  reverse,  respectively;  M13F:
TGTAAAACGACGGCCAGT  and  M13R:  CAGGAAACAGCTAT-
GACC)  building  36  mer  and  38  mer  primers,  respectively.
The  primer  sequences  were  as  follows:
Tel1F:  CCCCATTAGTGAGTCTTGGC
Tel1R:  GCTCAGTGAGGGTGCTCTGG
Tel2F:  GGAGAGCAAAGGGGAACCAC
Tel2R:  AGATGGGCAGCGGCAGTACC
Tel3F:  CCTGGCTGATGATGCGGA
Tel3R:  GGGACATGGAGCGGGACA
Tel4F:  CTTCGTCGCTCCCTGTCC
Tel4R:  CACCTCTTGCCCTCACCA
The  final  polymerase  chain  reaction  mix  (25  l)  con-
tained  about  20  ng  of  genomic  DNA,  200  M  dNTP,  0.1Please  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
M  each  primer,  0.625  U  AmpliTaq  Gold  DNA  polymerase
and  GeneAmp  10x  PCR  Buffer  (100  mM  Tris-HCl,  pH  8.3,
500  mM  KCl,  15  mM  MgCl2,  0.01%  (w/v)  gelatin,  Applied
Biosystems,  Darmstadt,  Germany).14 The  amplicons  were
g
e
o
c
Figure  1  Mutation  p.Cys57Trp  in  the  TCAP  gene.  A:  DNA  sequen
detected mutation  c.171C>G  in  individuals  II-1  and  II-2.  The  missens
arrow). Individual  II-3  exhibits  a  normal  electropherogram  (homozyg
amino acid  is  shown  below.  B:  Pedigree  of  the  identified  family.  Squ
unaffected individuals  and  solid  symbols  affected  individuals;  ques
data), and  slanted  bar,  a  deceased  individual.  The  presence  or  abse
symbol, respectively.  An  arrow  denotes  the  proband.  C:  Alignment  
conservation  in  mammals  (from  chimp  to  dolphin)  but  no  conservatio
in the  human  sequence  is  underlined. PRESS
y  with  HCM  3
nalyzed  by  direct  sequencing  using  ABI  Big  Dye  Termi-
ator  chemistry  and  run  on  an  ABI  3100  Avant  device
Applied  Biosystems,  Darmstadt,  Germany)  as  per  the  man-
facturer’s  instructions.  Detected  variants  in  a  sample  were
onfirmed  in  at  least  two  independent  PCRs  and  sequenc-
ng  runs.  Sequencher  software  version  4.8  (Gene  Codes,
nn  Arbor,  MI,  USA)  was  used  to  facilitate  data  analysis
nd  mutation  identification  followed  by  visual  inspection  of
ndividual  sequencing  traces.6 Genetic  variants  were  anno-
ated  according  to  the  cDNA  and  protein  reference  sequence
Ensembl  ID  ENST00000309889.2  and  UniProtKB/Swiss-Prot
D  O15273).
The  most  common  HCM-associated  genes,  the  beta-
yosin  heavy  chain  (MYH7) and  the  myosin-binding  protein
 (MYBPC3)  and  other  disease  genes  (TNNT2,  TNNI3, TPM1,
YL2,  MYL3,  ACTC1,  TNNC1, MYOZ2,  and  MLP) were  sys-
ematically  screened,  as  we  and  other  colleagues  have
reviously  published.9,16--20 Disease-causing  mutations  in
ll  eleven  genes  were  excluded  in  the  proband;  other of  a novel  titin-cap/telethonin  mutation  in  a  Portuguese
20.  https://doi.org/10.1016/j.repc.2019.12.007
enes  were  not  analyzed.  The  TCAP  mutation  was  also
xcluded  in  400  unrelated  controls  of  Caucasian  origin  with-
ut  hypertrophy  and  dilation  and  400  subjects  with  dilated
ardiomyopathy.14
cing  electropherograms  demonstrating  heterozygosity  for  the
e  mutation  is  shown  as  two  overlapping  peaks  (marked  with  an
ous  C).  Codons  are  marked  with  gray  blocks  and  the  respective
ares  represent  males;  circles  females.  Open  symbols  indicate
tion  marks,  individuals  with  unknown  status  (without  clinical
nce  of  the  mutation  p.C57W  is  indicated  by  a  plus  and  minus
of  orthologs  from  eleven  different  species  demonstrating  high
n  in  distantly  related  species  such  as  fish.  The  mutated  residue
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Further  analysis  was  performed  by  considering  the  fre-
uency  in  population-based  datasets,  such  as  the  Exome
ggregation  Consortium  (ExAC)21 and  the  Genome  Aggre-
ation  Database  (gnomAD).22 The  latter  consists  of  141,456
uman  exomes  and  genomes  (aligned  against  the  GRCh37
eference).  We  also  assessed  the  possible  functional  impact
sing  seven  different  variant  prediction  algorithms,  namely
utationTaster,23 M-CAP,24 PolyPhen2,25 SIFT,26 PROVEAN,27
utation  Assessor28 and  REVEL.29 These  were  not  used  in
ombination.
esults
dentification  of  the  p.C57W  mutation
fter  exclusion  of  mutations  in  the  eleven  differ-
nt  HCM  disease  genes  described  above,  we  identified
he  novel  heterozygous  missense  mutation  c.171C>G
chr17:37822028C>G;  dbSNP  ID  rs369447207)  in  exon  2
f  the  TCAP  gene  in  one  HCM  patient,  individual  II-
,  the  proband  of  the  identified  family  (Figure  1A
nd  1B).  It  leads  to  an  exchange  of  tiny  cysteine  to
arge  aromatic  tryptophan  at  codon  57  (p.C57W),  twoPlease  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
mino  acids  with  strong  differences  in  their  physical  and
hemical  properties.  The  mutation  affected  both  known
CAP  transcripts  (TCAP-201/ENST00000309889.2  and  TCAP-
02/ENST00000578283.1).
c
t
F
igure  2  Distribution  of  mutations  in  the  titin-cap  protein  and  kn
s located  in  the  muscle  LIM  protein  and  titin  interacting  domain.  
isplayed. Red  arrows  indicate  mutations  in  HCM  patients  and  blue
rrows denote  three  variations,  which  were  initially  described  as  m
ssociated because  of  their  frequency.  The  known  interaction  partner
: Titin-cap  interacts  with  a  variety  of  different  proteins  in  the  Z-dis
he potassium  channel  subunit  minK,  muscle  LIM  protein  (MLP),  and
o Frank  et  al.53).  Please  note  we  present  only  a  selection  of  known PRESS
A.  Toste  et  al.
The  mutation  is  located  in  overlapping  domains  of  titin-
ap/telethonin,  which  are  involved  in  the  binding  of  titin
nd  muscle  LIM  protein  (MLP),  two  important  sarcomere  pro-
eins  in  the  pathogenesis  of  cardiomyopathies  (Figure  2A).
he  identified  variant  is  very  rare  with  a minor  allele  fre-
uency  (MAF)  of  0.00003  (three  alleles  identified  out  of
 total  of  96  076  alleles  analyzed)  in  the  ExAC  database
s  well  as  in  gnomDB  (four  in  108  136;  European  popula-
ion),  confirming  the  assumption  that  pathogenic  variants
re  very  rarely  detected  in  the  general  population.  The
utation  was  also  excluded  in  800  control  alleles  we  ana-
yzed.
Alignment  of  different  orthologs  surrounding  the  affected
odon  57  showed  very  high  conservation  through  evolution
n  mammals  (from  chimp  to  dolphin),  suggesting  functional
mportance  (Figure  1C).  However,  the  residue  shows  no
onservation  in  distantly  related  species  such  as  fish.  Fur-
her  in  silico  analysis  using  seven  bioinformatic  prediction
ools  led  to  conclusive  results  concerning  the  identified
utation:  all  of  them  predicted  the  variant  to  be  damag-
ng/deleterious.
In  addition  to  the  proband,  two  further  family  members
individuals  II-2  and  II-3)  were  examined  and  analyzed.  The
henotype  co-segregates  with  the  genotype:  both  mutation of  a  novel  titin-cap/telethonin  mutation  in  a  Portuguese
20.  https://doi.org/10.1016/j.repc.2019.12.007
arriers  were  affected,  while  the  family  member  without
he  mutation  (II-3)  had  a  normal  phenotype  (see  pedigree  in
igure  1B).
own  interaction  partners.  A:  The  identified  mutation  p.C57W
All  published  mutations  associated  with  cardiomyopathies  are
 arrows  mutations  in  dilated  cardiomyopathy  patients.  Orange
utations,  but  seem  to  be  actually  benign  rather  than  disease-
s  of  titin-cap  are  shown  below  the  bar  representing  the  protein.
k.  In  addition  to  the  N-terminus  of  two  titin  molecules,  it  binds
 all  three  members  of  the  calsarcin  protein  family  (according
 interaction  partners  in  this  figure.
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Figure  3  Echocardiogram  from  the  index  patient  II-1  (performed  at  the  age  of  54).  Parasternal  long  axis  view,  two-dimensional
and M-mode,  showing  asymmetric  septal  hypertrophy  and  mitral  valve  systolic  anterior  motion.  Apical  four  chamber  view  and  color
wave Doppler  show  major  left  ventricular  outflow  tract  obstruction.  Please  note  that  these  18-years-old  echocardiographic  images
es  f
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care suboptimal  quality  since  they  were  obtained  from  still  fram
images available.
Clinical  vignettes
Hypertrophic  cardiomyopathy  was  first  diagnosed  in  the
female  proband,  individual  II-1  (Figure  1B)  at  the  age  of
45  years  when  she  developed  paroxysmal  atrial  fibrillation
(AF)  after  non-cardiac  surgery.  At  that  time,  she  was  clas-
sified  in  New  York  Heart  Association  (NYHA)  class  II.  Her
physical  examination  revealed  a  systolic  murmur  at  the  left
sternal  border  and  aortic  area  that  increased  during  ortho-
statism.  The  ECG  showed  sinus  rhythm,  left  atrial  dilatation,
left  axis  deviation,  pathological  Q  waves  in  aVF  and  DIII,  V1
to  V4,  and  SV2+RV6=35  mm,  without  ST-T  changes.  Transtho-Please  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
racic  echocardiography  showed  asymmetrical  hypertrophy
of  the  anterior  and  inferior  septum  (neutral  septal  mor-
phology)  and  lateral  wall  (maximal  wall  thickness  20  mm),
without  apical  involvement  (Figure  3).  The  left  ventricle  was
a
a
n
Figure  4  Electrocardiograms  from  patient  II-2.  A:  ECG  in  sinus  rhy
years later,  atrial  fibrillation.  C:  24-hour  ECG  monitoring  strip  from
triplet.rom  thermal  paper.  Unfortunately,  there  are  no  better  quality
on-dilated  and  left  ventricular  (LV)  ejection  fraction  was
reserved.  The  left  atrium  (LA)  was  dilated  and  there  was
vidence  of  elevated  LV  filling  pressures  (E/e′15+LA  dilata-
ion+tricuspid  regurgitation  velocity>2.8  m/s).  The  resting
eak  left  ventricular  outflow  tract  (LVOT)  gradient  was  61
m  Hg  and  mild  to  moderate  systolic  anterior  motion  (SAM)
ependent  mitral  regurgitation  was  present.  Systolic  pul-
onary  artery  pressure  was  estimated  at  43  mmHg  (38+5).
issue  Doppler  imaging  showed  low  s’  and  e’  velocities  at
he  mitral  annulus.  CMR  was  not  performed.  She  began  to
ake  bisoprolol  and  oral  anticoagulation  (subsequently  dis-
ontinued  because  of  concomitant  alcoholic  liver  disease) of  a novel  titin-cap/telethonin  mutation  in  a  Portuguese
20.  https://doi.org/10.1016/j.repc.2019.12.007
nd  remained  clinically  stable  for  14  years.  She  died  in  2003
t  the  age  of  59,  from  a  liver  disease  complication;  she  had
o  offspring.
thm,  ST-T  segment  abnormalities  from  V3  to  V6.  B:  ECG,  three
 patient  II-2,  documenting  atrial  fibrillation  and  a  ventricular
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The  affected  brother  (individual  II-2),  now  aged  86,  has
n  HCM  phenotype,  detected  when  he  was  67  after  genetic
ascade  screening.  Although  asymptomatic  at  diagnosis,
e  developed  AF  and  has  slow-progressing  congestive  right
eart  failure,  now  in  NYHA  III,  with  multiple  hospitalizations
n  the  past  year.  He  reports  no  chest  pain  or  syncope.  His  firstPlease  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
CG  (Figure  4A)  showed  sinus  rhythm,  no  LV  hypertrophy
riteria  and  marked  ST-T  changes  in  the  precordial  leads.
is  echocardiogram  showed  asymmetric  hypertrophy,  neu-
ral  septal  morphology  (21  mm  maximal  wall  thickness)  and
i
i
i
a
igure  5  Echocardiogram  and  cardiac  magnetic  resonance  imag
ransthoracic echocardiogram,  parasternal  long  axis  view,  2-dimensi
: These  cardiac  magnetic  resonance  images  confirm  the  echocardiog
egurgitation)  and  provide  tissue  characterization  data,  with  late  g
ight ventricular  insertion  point  in  interventricular  septum,  typical  fi PRESS
A.  Toste  et  al.
o  obstruction,  neither  at  rest  nor  with  bedside  provocation
aneuvers  (Figure  5A).  LV  ejection  fraction  was  preserved.
hen  in  sinus  rhythm  the  E/e’  was  17.  The  right  chambers
ere  dilated  and  the  right  ventricle  had  reduced  longitudi-
al  function.  He  also  had  moderate  pulmonary  hypertension,
5  mmHg  (45+10).  His  CMR  revealed  intramural  late  gadolin- of  a  novel  titin-cap/telethonin  mutation  in  a  Portuguese
20.  https://doi.org/10.1016/j.repc.2019.12.007
um  enhancement  in  the  hypertrophic  segments,  as  well  as
n  the  insertion  zone  of  the  right  ventricle  in  the  lower
nterventricular  septum  (Figure  5B).  Later,  he  developed  AF,
nd  right  axis  deviation  (Figure  4B).  There  is  no  evidence
ing  from  patient  II-2  (performed  at  the  age  of  84  years).  A:
onal  and  M-mode,  also  showing  asymmetric  septal  hypertrophy.
raphic  findings  (asymmetric  septal  hypertrophy  and  mild  mitral
adolinium  enhancement  in  the  interventricular  septum  and  in
ndings  of  HCM.
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Table  1  Clinical  and  imaging  data  of  the  family  members.
Proband  (II-1)  Affected  brother  (II-2)  Non-affected
sister  (II-3)
ECG  LA  dilatation,  left  axis  deviation,
pathological  Q  waves  in  avF  and  DIII,
V1  to  V4,  LVH  criteria,  no  ST-T
changes
No  LVH  criteria,  T  wave
inversion→right  axis  deviation
Normal
Echocardiogram  Septal+lateral  wall  hypertrophy,  max
20 mm
Preserved  EF
LVOTO:  present
Mild  to  moderate  MR,  SAM  dependent
LA  dilation
Asymmetric  septal  hypertrophy,  max
21 mm
Preserved  EF
LVOTO:  absent
MV  prolapse  with  mild  MR
LA dilation
No  hypertrophy
Cardiac magnetic  resonance  Not  performed  (died  2003)  LGE  in  areas  of  hypertrophy  and  in
the  insertion  zone  of  the  right
ventricle  in  the  lower
interventricular  septum
Not  performed
Arrhythmias Paroxysmal  atrial  fibrillation  Paroxysmal→Permanent  atrial
fibrillation
Not  detected
Risk of  SCD  5  years  (ESC)  2.21%  2.61%  Not  applicable
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cEF: ejection fraction; LA: left atrium; LGE: late gadolinium enha
outflow tract obstruction; MR: mitral regurgitation; MV: mitral va
of  significant  ventricular  arrhythmias  other  than  a single
asymptomatic  ventricular  triplet  in  the  24-h  ECG  monitoring
(Figure  4C).  His  European  Society  of  Cardiology  (ESC)  HCM
Risk-SCD  is  low  (five-year  risk  <4%).3 Concomitant  pulmonary
embolism  was  excluded.  He  is  currently  taking  rivaroxaban,
bisoprolol,  furosemide  and  spironolactone.
The  proband’s  sister  (individual  II-3)  is  74  years  old  and
exhibited  no  HCM  phenotype.  Her  physical  examination,  ECG
and  echocardiography  were  normal.  Her  genetic  test  was
negative  for  the  p.C57W  mutation  in  the  TCAP  gene.
Discussion
In  a  small  family  of  Portuguese  origin,  we  identified  the  TCAP
mutation,  p.C57W.  It  demonstrated  a  very  low  population
frequency  and  there  is  strong  evidence  for  co-segregation
with  the  HCM  phenotype,  as  well  as  high  conservation  across
species.
Considerations  about  the  phenotype
Since  there  are  only  two  patients  in  this  family  with  the
p.C57W  mutation,  it  is  impossible  to  draw  definitive  conclu-
sions  about  clinical  presentations  and  genotype-phenotype
correlations.  Additionally,  as  the  index  patient  died  prema-
turely  of  a  non-cardiac  condition,  only  a  short  follow-up  of
this  patient  is  available.
Nonetheless,  the  two  patients  shared  some  common
features:  HCM  was  symptomatic  in  both  and  presented  in
adulthood,  and  was  relatively  late  in  onset.  This  corrob-Please  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
orates  data  on  the  Portuguese  population  in  the  recently
published  Portuguese  registry  of  HCM.30 The  major  com-
mon  imaging  features  were:  moderate  asymmetric  septal
hypertrophy,  dilated  LA,  increased  LV  filling  pressures,
g
b
p
pent; LVH: left ventricular hypertrophy; LVOTO: left ventricular
AM: systolic anterior motion.
ymptomatic  AF  and  heart  failure  with  preserved  ejection
raction.  (Tables  1  and  2) There  was  no  history  of  sudden
ardiac  death  (SCD)  or  malignant  ventricular  arrhythmias.
he  ESC  score-based  SCD  risk3 was  low  (Table  1),  in  contrast
ith  data  from  two  Japanese  families  with  TCAP  mutations,
n  whom  three  cases  of  SCD  were  found.10
Remarkably,  two  other  mutations  described  in  the  liter-
ture  are  close  to  the  one  found  in  this  study  (Figure  2).
he  p.R70W  mutation  was  described  in  a  symptomatic  HCM
atient  with  massive  hypertrophy  and  LVOT  obstruction  who
ubsequently  underwent  a  myectomy.31 Interestingly,  the
atient  was  of  Hispanic  origin.  Additionally,  Hershberger
t  al.  found  the  variant  p.E49K  in  a  patient  with  idiopathic
ilated  cardiomyopathy.  The  phenotype  in  this  case  was  not
escribed  any  further.32
Finally,  Theis  et  al.  studied  239  myofilament  genotype
egative  HCM  patients.33 In  13  of  these  subjects,  they  found
 Z-disk  mutation,  and  sigmoidal  morphology  was  the  pre-
ominant  phenotype  (85%).  One  of  these  13  patients  carried
he  p.R70W  TCAP  mutation,  and  this  patient  also  had  a
igmoid  septum.  These  authors  suggest  that  Z-disk  HCM  is
ssociated  preferentially  with  sigmoidal  morphology.  In  the
resent  study,  however,  we  describe  a family  carrying  a  new
CAP  mutation  whose  phenotype  has  neutral  septal  mor-
hology.
CAP  mutations
s  shown  by  several  studies,  TCAP  mutations  identified  in
ardiomyopathy  patients  are  distributed  over  the  whole of  a novel  titin-cap/telethonin  mutation  in  a  Portuguese
20.  https://doi.org/10.1016/j.repc.2019.12.007
ene/protein10,31,33--38 (Figure  2A)  and  the  differentiation
etween  true  pathogenic  mutations  and  benign  polymor-
hisms  is  challenging.  One  example  is  the  in-frame  deletion
.Glu13del  initially  described  by  Bos  et  al.  as  pathogenic,31
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Table  2  Detailed  echocardiographic  data  of  the  family  members.
Proband  (II-1)  Affected  brother  (II-2)  Non-affected  sister  (II-3)
IVS  (mm)  20  21  9
LVPWd (mm)  12  8  8
LVEDD (mm) 43  48  47
LVESD (mm)  17  29  26
LVOTO (mmHg)  61  9  7
LA-AP diameter  M-mode  (mm)  43  55  34
IVS: interventricular septum; LA-AP: anterior-posterior dimension of the left atrium; LVEDD: left ventricular end diastolic diameter;
LVESD: left ventricular end systolic diameter; LVOTO: left ventricular outflow tract obstruction; LVPWd: left ventricular posterior wall
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hich  we  and  many  others  have  shown  is  benign  because
f  its  frequency.14,39 This  was  subsequently  confirmed  by
 now  publicly  available  resource,  the  ExAC  database,
howing  a  MAF  of  0.00095  for  this  variant  (115  found  alle-
es  out  of  95  905  alleles  analyzed  in  total).  The  same
s  true  for  p.R153H,10 which  seems  frequently  to  be  a
athogenic  variant  (MAF  0.00017;  20/119  294  alleles).  In
ontrast,  the  p.C57W  mutation  identified  in  this  study  is
 very  rare  variant  (MAF  0.00003)  with  similar  frequency
s  the  abovementioned  p.R70W  (MAF  0.00002).  This  is  in
ine  with  the  threshold  MAF  of  0.0001  for  HCM  suggested  by
alsh  et  al.38
The  mutation  spectrum  in  the  Portuguese  HCM  population
eems  similar  to  the  published  data.  MYBPC3  and  MYH7  are
he  most  frequent  disease  genes,  followed  by  cardiac  tropin
 (TNNT2)  and/or  cardiac  tropin  I  (TNNI3),  as  demonstrated
n  studies  by  Cardim  et  al.,16 Brito  et  al.,40 Santos  et  al.,41
nd  Mendes  de  Almeida  et  al.42 Santos  et  al.  analyzed  80  HCM
atients  using  a  panel  of  28  HCM-associated  genes,  includ-
ng  TCAP, but  no  mutation  was  identified  in  that  gene.41
endes  de  Almeida  et  al.  screened  16  HCM  patients  for
CAP  and  25  other  HCM-associated  genes  and  also  failed  to
etect  a  TCAP  mutation.42 It  is  notable  that  when  analyzing
ndividuals  of  Spanish  origin,  the  study  by  Mademont-Soler
t  al.  included  a  large  cohort  of  303  HCM  patients  who
ere  screened  by  next-generation  sequencing  in  20  HCM-
ssociated  genes.43 They  only  found  one  TCAP  variant  of
nknown  significance  (p.R33W)  in  a  patient  who  also  carried
 known  pathogenic  MYH7  mutation.  It  is  of  interest  that  the
CAP  gene  was  also  screened  in  Portuguese  patients  with
ilated  cardiomyopathy  (n=107)  and  this  also  revealed  only
ne  variant  of  unknown  significance  (p.E105Q).44,45 TCAP
utations  are  very  rare  which  makes  the  few  identified
ariants  and  affected  families  all  the  more  interesting  and
articularly  intriguing.
Titin-cap  is  also  involved  in  genetic  skeletal  muscle  dis-
ase,  autosomal  recessive  limb  girdle  muscular  dystrophy
ype  2G  (LGMD2G),  which  manifests  in  proximal  muscles
f  the  hip  and  shoulder  girdles,  and  may  be  associated
ith  cardiac  involvement.46,47 One  particularly  noteworthy
bservation  concerning  our  study  is  that  among  patients  with
GMD2G  due  to  titin-cap  deficiency,  the  most  commonlyPlease  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
eported  TCAP  mutation  p.Gln53Ter  has  been  identified  in
nly  one  patient  from  Portugal48 and  Brazilian  patients.49--51
he  latter  may  be  related  to  the  long  history  of  Portuguese
migration  to  Brazil.
c
b
p
motential  effects  of  the  mutation
itin  filaments  form  an  uninterrupted  connective  link  along
he  myofibers  and  are  crosslinked  at  the  Z-disk  by  titin-
ap/telethonin.52 This  small  protein  forms  an  antiparallel
andwich  complex  with  two  N-terminal  domains  of  titin
referred  to  as  Z1/Z2)  at  the  Z-disk  edge,  demonstrat-
ng  extraordinary  mechanical  stability,  gluing  two  titin
olecules  together  (Figure  2B).53--55 Titin-cap  has  a  unique
longated  3D  structure  with  a  central,  five-stranded,
ntiparallel  -sheet  that  is  extended  by  two  exposed  wing-
haped  -hairpin  motifs  (A-B  and  C-D).53 The  p.Cys57Trp
utation  is  located  in  the  wing-2  motif  (C-D).  There,  cys-
eine  forms  hydrogen  bonds  with  arginine  at  position  33
f  titin-cap.  The  structural  integrity  of  the  Z-disk  depends
pon  the  tight  network  of  the  hydrogen  bonds  between
omains  Z1/Z2  and  titin-cap.  These  bonds  enable  the  com-
lex  to  resist  extremely  high  mechanical  loads.51,56 If  tiny
ulfur-containing  cysteine  is  exchanged  with  large  aromatic
ryptophan,  this  may  lead  to  a  weakening  or  even  a  disrup-
ion  of  the  core  -sheet  structure  of  the  titin-cap  protein,
hich  may  disturb  the  binding  of  titin  domains  Z1  and  Z2.
his  could  subsequently  lead  to  changes  in  the  elasticity  and
tress  resistance  of  sarcomeres.  A  possible  correlate  at  tis-
ue  level  may  be  myocyte  disarray,  a  pathological  hallmark
f  HCM.57 Unfortunately,  we  were  not  able  to  analyze  this
irectly  in  this  patient.
The  p.C57W  mutation  is  located  in  the  domain  (residues
3-81)  binding  MLP  (Figure  2A  and  2B),  an  important  compo-
ent  of  the  stretch  sensor  machinery  of  the  cardiac  Z-disk.34
t  is  noteworthy  that  we9 and  other  authors31 have  linked  the
utations  in  CSRP3  encoding  MLP  to  HCM.
To  elucidate  the  true  functional  effects  of  the  muta-
ion,  mechanistic  studies,  including  the  in  vitro  expression
f  the  mutation  in  cultured  cardiomyocytes,  as  well  as
n  vivo  expression  in  animal  models  (mouse,  zebrafish,  and
rosophila)  may  be  promising.  Novel  technology,  such  as
RISPR/Cas9,  could  be  used  to  engineer  precise  knock-in
odels  much  faster  than  before.58 Another  very  promis-
ng  approach  for  investigating  the  molecular  mechanism
f  individual  mutations  underlying  HCM  is  patient-derived
nduced  pluripotent  stem  cells,  from  which  cardiomyocytes
59 of  a  novel  titin-cap/telethonin  mutation  in  a  Portuguese
20.  https://doi.org/10.1016/j.repc.2019.12.007
an  be  derived  in  vitro. This  was  recently  demonstrated
y  Feng  et  al.  who  reported  that  abnormal  calcium  handling
roperties  underlie  familial  HCM  caused  by  an  MYH7
utation.60
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Study  limitations
There  may  be  some  limitations  to  the  present  study.
Although  we  have  excluded  mutations  in  11  known  HCM
disease  genes,  we  cannot  rule  out  the  presence  of  other
pathogenic  variants  in  other  genes.  Functional  studies  may
have  helped  to  clarify  the  relevance  of  p.C57W,  but  this  was
beyond  the  scope  of  this  study,  and  further  investigations
to  elucidate  its  functional  impact  are  needed.  Although  the
location  of  the  mutation  in  an  important  domain  involved
in  anchoring  the  proximal  end  of  titin  (considering  the
known  3D  protein  structure)  makes  a  functional  effect  highly
probable,  this  consideration  is  so  far  only  speculation.  Fur-
ther  robust  linkage  was  hindered  by  the  small  size  of  the
family.  However,  the  phenotype  co-segregated  clearly  with
the  genotype.  Additionally,  the  exclusion  of  disease-causing
genes  in  the  patient,  the  identification  of  a  variant  in  an
established  HCM  gene,  the  confirmation  of  a  very  low  fre-
quency,  the  high  conservation  of  the  affected  amino  acid,
and  the  clear  and  conclusive  results  from  the  prediction
tools  strongly  support  our  classification  of  p.C57W  as  a  likely
disease-causing  mutation.
Conclusions
A  novel  TCAP  mutation  in  a  small  family  with  HCM  was
identified  and  evidence  supporting  the  classification  of  the
mutation  as  a  likely  pathogenic  variant  was  presented.  The
genetic  diversity  that  underlies  HCM,  a  prototypic  single-
gene  disorder,  remains  a  complex  issue.1 Although  TCAP
mutations  seem  to  be  a  very  rare  cause  of  HCM,  we  have
highlighted  another  interesting  TCAP  mutation,  and  hope
to  shed  some  light  on  this  underrepresented  orphan  HCM
disease  gene.
Key points
What  is  known  about  the  topic?
HCM  is  a  sarcomeric  disease  but  the  genetic  test  for
the  classical  disease-causing  genes  is  negative  in  more
than  1/3  of  the  patients.  In  recent  years,  mutations  in
Z-  disk  proteins  have  been  proposed  as  potential  addi-
tional  disease-causing  genes,  but  scientific  evidence  of
this  hypothesis  is  still  scarce.
What  does  this  study  add?
After  exclusion  of  mutations  in  eleven  different  HCM
disease  genes,  we  present  data  supporting  the  classifi-
cation  of  the  TCAP  missense  mutation  p.C57W  encoding
the  Z-disk  protein  titin-cap/telethonin  as  a  new  likely
pathogenic  variant  for  HCM,  with  a  specific  phenotypePlease  cite  this  article  in  press  as:  Toste  A,  et  al.  Identification
family  with  hypertrophic  cardiomyopathy.  Rev  Port  Cardiol.  20
profile  in  the  analyzed  family. PRESS
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